Cyanvac

Industry: Production animal vaccines

CyanVac develops vaccines for production animals using parainfluenza virus 5 (PIV5) as a vector. The company is currently focused on developing vaccines for swine, with circovirus as the lead target.

Commercially available vaccines for porcine circovirus type 2 (PCV2) can lower both incidence and severity, but they do not prevent infection. Cell-mediated immune responses are important for clearing PCV2 infection -- yet none of the PCV2 vaccines on the market can generate these responses.

The animal health market is valued at over $22.5 billion in the U.S. alone. Vaccines have become the most important health management tool for modern pig production, and swine vaccines account for almost half of all livestock vaccine revenue. In addition, PCV2 vaccines are among the most profitable swine vaccines.

Back to companies